Coley at neutral by Merrill

Merrill Lynch analyst Tom McGahren rated Coley Pharmaceutical Group Inc. at neutral on updated data from a phase 1b study for Actilon in hepatitis C (HCV) showed that continuation on treatment with Actilon plus Pegylated interferon plus Ribavirin resulted in sustained or improved HCV RNA undetectability beyond week 12. The analyst looks for phase 1b sustained viral response data in the first half of 2007 and early viral response data from a phase 2 study by the end of 2006. Shares of the Wellesley, Mass.-based pharmaceutical company were up 1 cent, or 0.09%, at $11.53. (Nasdaq: COLY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.